A Critical Review of WHO’s List of Antibacterials in Clinical Development

WHO compiles a list of antibacterials in clinical development on a regular basis, the last in mid-2024 [1].  The information is up-to-date and detailed: it provides MoA and antibacterial spectrum, coverage of problem pathogens, the development phase, and whether it can be considered an ‘innovative’ drug (based on a set Continue reading A Critical Review of WHO’s List of Antibacterials in Clinical Development

Some Thoughts about the New Coronavirus Syndrome and its Transmission

First and upfront, let’s call this virus WARS*, which stands for Wuhan Associated Respiratory Syndrome.  President Xi Jingping called for a war against the new virus, and a war it is.  Therefore our acronym makes intuitive sense.  The naming of new viruses is getting politized and silly: yes, we need Continue reading Some Thoughts about the New Coronavirus Syndrome and its Transmission

FDA Needs Radical Reform

The nomination of Dr. Scott Gottlieb for FDA commissioner, a political appointee, has created the usual bipartisan furor. He is called unqualified, a renegade, not committed enough to FDA orthodoxy, an industry darling by some and a maverick by others. All the while FDA lobbyists are singing the praises of an Continue reading FDA Needs Radical Reform